Magnetocardiography as a Tool for Patients Presenting With Chest Pain - Pilot Study

Chest Pain Clinical Trial

Official title:

Two Cohort, Pilot Study, to Identify Magnetocardiogram Characteristics That Can be Used to Classify Non Ischemic Chest Pain Patients and Myocardial Infarction Patients.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02359773
• Other study ID #: QI CIP 001 Rev 001
• Status: Completed
• Phase: N/A
• First received: January 12, 2015
• Last updated: August 3, 2015
• Start date: February 2015
• Est. completion date: August 2015

Study information

• Verified date: February 2015
• Source: Quantum Imaging Limited
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Observational

Clinical Trial Summary

The purpose of this pilot research study is to identify the characteristics of magnetocardiograms that correlate with a non ischemic chest pain status and a myocardial infarction patient status. The study uses a non SQUID magnetocardiogram device.

Description:

Magnetocardiography (MCG) is a passive, non-contact technique to measure the electromagnetic activity of the heart.

Heart muscle is controlled by electrical impulses that initiate contraction of the myocardium to pump blood around the body. A wave of depolarisation and repolarisation helps to coordinate the heart's activity which is usually measured using an electrocardiogram (ECG) which reflects the surface electrical manifestation of myocardial depolarisation and repolarisation

For every electrical signal there is a corresponding magnetic field, as defined by Faraday's law of induction, and it is this magnetic field that MCG measures.

There are two key advantages of looking at the magnetic field rather than the electrical signal. (1) The signal is not attenuated as it passes through the body, so information is not lost and (2) changes in the action potential (for example those caused by ischemia) are 'magnified' in the magnetic field so are easier to detect by sensors that are not in direct contact with the body.

SQUID MCG has been used widely in cardiology research, and previous clinical studies have shown that the technology has potential for the analysis of patients with coronary artery disease.

The aim of this pilot study is to identify characteristics of MCG that differentiate patients with non-ischaemic chest pain from those with a myocardial infarction.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: August 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Non ischemic chest pain subject inclusion criteria

• Subjects will be males or females over the age of 18.

• Subjects will have experienced chest pain within the last 8 weeks and have been subsequently referred to the rapid access chest pain clinic (RACPC).

• Subjects will have no coronary artery disease/ischemia as demonstrated by one of the following: MRI, myoview or stress echo within no less than 4 weeks prior to the magnetocardiogram (MCG) scan.

• Subjects will have given written informed consent to participate in the study.

Myocardial Infarction subject inclusion criteria

• Subjects will be males or females over the age of 18.

• Subjects will have experienced chest pain and have been admitted to the cardiology unit.

• Subjects will have an abnormal level of Troponin (=50ng/l) taken at 12 hours following the onset of chest pain.

• Subjects will be suitable to have an MCG scan taken within 48 hours of the onset of chest pain and prior to coronary angioplasty or any other surgical intervention.

• Subjects will have given written informed consent to participate in the study.

Exclusion Criteria:

Non ischemic chest pain subject exclusion criteria

• Subjects with symptoms suggestive of acute coronary syndrome that require further investigation.

• Subjects who had an abnormal level of Troponin (=50ng/l) - as determined by a test performed prior to referral to the RACPC.

• Subjects who have a pacemaker or internal cardiac defibrillator.

• Subjects with an active implantable device.

• Subjects with ferrous implants in the torso including wires or ferrous stents.

• Subjects who are pregnant.

• Subjects who are unable to lie in a supine position.

• Subjects with any comorbidity that prevents them being scanned.

Myocardial Infarction subject exclusion criteria

• Subjects who have had a STEMI.

• Patients with haemodynamic instability (dysrhythmia or hypotension).

• Subjects who have had a revascularisation technique performed prior to an MCG scan.

• Subjects who have a pacemaker or internal cardiac defibrillator.

• Subjects with ferrous implants in the torso including wires or ferrous stents.

• Subjects with an active implantable device.

• Subjects who are pregnant.

• Subjects who are unable to lie in a supine position.

• Subjects with any comorbidity that prevents them being scanned.

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Chest Pain
• Myocardial Infarction

Locations

Country	Name	City	State
United Kingdom	Leeds Teaching Hospitals NHS Trust	Leeds	West Yorkshire

Sponsors (1)

Lead Sponsor	Collaborator
Quantum Imaging Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Magnetocardiogram Characteristics in patients with chest pain	Quantitative comparison of magnetocardiogram characteristics of non ischaemic chest pain patients compared to those with an acute myocardial infarction	1 hour	No
Secondary	Device Safety	Any adverse effects, adverse device effects, Unanticipated serious device effects	At time of scan for all patiients (Varies)	Yes

External Links

•   Quantum Imaging Website